Streetbeat News

Regulatory

CNTA

The FDA has approved Centessa Pharmaceuticals' application to begin a Phase 1 clinical trial of ORX750, a new drug aimed at treating narcolepsy. This marks a significant step for Centessa in advancing its pipeline and potentially addressing a critical need in narcolepsy treatment.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:09 am

MRNA

Moderna has secured a contract with Brazil's Ministry of Health to supply 12.5 million doses of its mRNA COVID-19 vaccine, scheduled for delivery in Q2 2024. This follows the Brazilian Health Regulatory Agency's approval of Moderna's updated COVID-19 vaccine in March 2024.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:06 am

PSTV

Plus Therapeutics Inc (NASDAQ:PSTV) is set to receive a $3 million funding recommendation from the Department of Defense for expanding its pediatric brain cancer clinical trial. The funding, expected to start in Q3 2024, will support the trial's expansion and extend the company's cash runway into the second half of 2025. Plus Therapeutics is focusing on a novel therapeutic, Rhenium (186Re) Obisbemeda, for treating pediatric high-grade glioma and ependymoma, with patient enrollment anticipated in the second half of 2024.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 11:00 am

PSTV

Plus Therapeutics, Inc. has been recommended for a $3 million award by the U.S. Department of Defense. This funding is aimed at supporting the company's research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:00 am

HMC

Canada is close to finalizing a deal with Honda Motor Co. (NYSE:HMC) to manufacture electric vehicles (EVs) and components in Ontario, involving the construction of new facilities with government subsidies. This move is part of Canada's efforts to attract EV sector investments and positions Ontario as a key hub for Honda's North American EV manufacturing. The deal includes investment tax credits and is expected to be announced within a week.

Portfolio Pulse from Shivani Kumaresan

April 22, 2024 | 10:28 am

SUUN

SolarBank Corporation (NASDAQ:SUUN) has signed lease agreements for five sites in Orleans County, New York, totaling 94 acres for the development of a 30 MW DC solar power project. These projects are expected to qualify for incentives under the New York State Energy Research and Development Authority (NYSERDA) NY-Sun Program.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 7:48 am

AAPL

HOOD

ICE

NVDA

The New York Stock Exchange (NYSE), part of Intercontinental Exchange (NYSE:ICE), is exploring the possibility of 24/7 trading, similar to cryptocurrencies like Bitcoin and Ethereum. This consideration is in response to increased retail investor activity and the continuous trading nature of cryptocurrencies. The NYSE is conducting a survey on this potential shift, while the SEC reviews a 24/7 exchange proposal backed by Steve Cohen's Point72. Companies like Apple Inc (NASDAQ:AAPL) and NVIDIA Corp (NASDAQ:NVDA), along with brokers like Robinhood Markets Inc. (NASDAQ:HOOD), are highlighted in the context of this discussion.

Portfolio Pulse from Benzinga Neuro

April 22, 2024 | 7:43 am

NBY

NovaBay Pharmaceuticals has been notified by NYSE American of a compliance issue related to stockholder equity. The company is required to address this issue to maintain its listing.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 7:31 am

FFIE

Faraday Future has received a non-compliance notice from Nasdaq due to a delay in filing its 10-K report. The notice is a standard procedure for companies that fail to meet Nasdaq's filing requirements. Faraday Future is expected to address this issue to avoid potential delisting.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 7:29 am

SDZNY

Sandoz, a division of Novartis, has received European Commission approval for Pyzchiva (ustekinumab), a biosimilar to the reference medicine, marking a significant step in strengthening its immunology portfolio. The approval is based on a comprehensive development program demonstrating Pyzchiva's similarity in safety, efficacy, and quality to the original medication. This approval highlights Sandoz's ongoing commitment to enhancing access to critical treatments in the field of immunology.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 6:45 am